FDA 483 - Denison Pharmaceuticals, LLC - July 29, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Denison Pharmaceuticals, LLC in Lincoln, RI, a human drug manufacturer, revealed significant deficiencies in quality control, facility maintenance, and production processes. The firm failed to adequately investigate numerous discrepancies, including OOS/OOT results, mold, and microbial contamination, and exhibited poor control over GMP documents, materials, and labeling. Additionally, the facility showed issues with cleanliness, pest control, and equipment maintenance, indicating a systemic lack of adherence to cGMP regulations.
ID · e4e9d792-bf44-4b54-b508-f0b77e37af5c